Citation Impact
Citing Papers
CYP2A6Polymorphisms and Risk for Tobacco-Related Cancers
2008
Nicotine Chemistry, Metabolism, Kinetics and Biomarkers
2009 Standout
Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence
2005
Pharmacogenetics of the Proton Pump Inhibitors: A Systematic Review
2003
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
2013 Standout
Prolonged residence of temperate natives in the tropics produces a suppression of sweating
2006
Polymorphism of human cytochrome P450 enzymes and its clinical impact
2009
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity*1
2004
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
2002
Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19
2001
Comparison of density and output of sweat gland in tropical Africans and temperate Koreans
2017
Tailoring Nicotine Replacement Therapy
2006
A Novel Duplication Type of CYP2A6 Gene in African-American Population
2007
STEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMES
2003
Metabolism and Disposition Kinetics of Nicotine
2005
Molecular Genetics of Nicotine Metabolism
2009
CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy ofHelicobacter pyloriinfection
2009
Diterpenoid and steroidal alkaloids
1997
Three haplotypes associated with CYP2A6 phenotypes in Caucasians
2005
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
2008 Standout
H pylori antibiotic resistance: prevalence, importance, and advances in testing
2004 Standout
Cytochrome P450 2A6 polymorphism in nasopharyngeal carcinoma
2005
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1‐week regimen of proton pump inhibitor, amoxicillin and clarithromycin
2003
Pharmacogenomics-based Tailored Versus Standard Therapeutic Regimen for Eradication of H. pylori
2007
High‐dose rabeprazole–amoxicillin versus rabeprazole–amoxicillin–metronidazole as second‐line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection
2003
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin
2001
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
PharmGKB summary
2011
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
2001
Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine
2013
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations
2006
International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding
2010 Standout
Nicotine replacement therapy for smoking cessation
2012 Standout
The Enigmatic Epidemiology of Nasopharyngeal Carcinoma
2006 Standout
Physiology of sweat gland function: The roles of sweating and sweat composition in human health
2019 Standout
Pathogenesis ofHelicobacter pyloriInfection
2006 Standout
Plant Products as Antimicrobial Agents
1999 Standout
Perspiration Functions in Different Ethnic, Age, and Sex Populations: Modification of Sudomotor Function
2016
Cytochrome P450-Mediated Drug Interactions
2000
Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study
2018 StandoutNobel
Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole
1999
Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of [alpha]2B adrenoceptors.
2000 StandoutNobel
Fluorine in health care: Organofluorine containing blockbuster drugs
2010 Standout
Genetic Variability inCYP2A6and the Pharmacokinetics of Nicotine
2007
Works of Jun‐Tack Kwon being referenced
Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism
2002
Characterization of Nicotine and Cotinine N-Glucuronidations in Human Liver Microsomes
2002
Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status*
1997
Nicotine metabolism and CYP2A6 allele frequencies in Koreans
2001
Cyclobuxine Protects the Isolated Rat Heart from the Myocardial Injuries Produced by Ischemia and Reperfusion
1993
The change in peripheral sweating mechanisms of the tropical Malaysian who stays in Japan
2004